Switching from combination antiretroviral therapy (cART) to dolutegravir (DTG) monotherapy in virologically suppressed HIV-1 infected adults: a randomized multicenter, non-inferiority clinical trial (DOMONO) - Ingeborg Wijting

European HIV Clinical Forum 2016

Induction-Maintenance ARV Therapy: Why, Who, When and How? - Pedro Cahn, MD, PhD

European HIV Clinical Forum 2016

Clinical Case Presentations - Experience with Induction-Maintenance Therapy in real life settings - José Arribas, MD

European HIV Clinical Forum 2016

Maintenance Therapy with Dolutegravir/Rilpivirin is efficient and well tolerated in a real-life setting - Katharina Grabmeijer Pfistershammer

European HIV Clinical Forum 2016

How to manage drug - drug interactions - the theory - Giovanni Di Perri, MD, PhD

European HIV Clinical Forum 2016

Study of early development of broadly neutralizing antibodies in HIV-1-infected infants - Cassandra Simonich, MD/PhD Candidate

International Workshop on HIV Transmission 2016

The fine specificity and autologous virus neutralization potency of maternal antibodies that predict reduced HIV-1 mother to child transmission - Sallie Permar, MD, PhD

International Workshop on HIV Transmission 2016

Studies in early acute infection and implications for transmission and cure - Merlin Robb, MD

International Workshop on HIV Transmission 2016

The Role of TAF in PrEP - Katy Garrett, PharmD

International Workshop on HIV Transmission 2016

Research update: drug development - Myron Cohen, MD

International Workshop on HIV Transmission 2016

Local situation in Turkey | Serhat Unal, MD

Central and Eastern European Meeting on Viral Hepatitis and HIV 2016

Local situation in Russia | Vadim Rassokhin, MD

Central and Eastern European Meeting on Viral Hepatitis and HIV 2016

State-of-the-art treatment of Hepatitis B | Cihan Yurdaydin, MD

Central and Eastern European Meeting on Viral Hepatitis and HIV 2016

Prospects for Cure | Patrick Kennedy

Central and Eastern European Meeting on Viral Hepatitis and HIV 2016

(Abstract) The effect of lamivudine- versus tenofovir-containing antiretroviral regimen on hepatitis B infection in a cohort of HIV infected long term survivors | A. Temereanca

Central and Eastern European Meeting on Viral Hepatitis and HIV 2016

(Abstract) The prevalence of HBV, HCV and HIV infection in Romania - a nationwide screening program for surveillance of viral infections | O. Sandulescu

Central and Eastern European Meeting on Viral Hepatitis and HIV 2016

IVDU | Pavel Khaykin, MD

Central and Eastern European Meeting on Viral Hepatitis and HIV 2016

Update of new drugs | Cihan Yurdaydin, MD

Central and Eastern European Meeting on Viral Hepatitis and HIV 2016

Drug-Drug Interactions: considerations | Anca Streinu-Cercel, MD, PhD

Central and Eastern European Meeting on Viral Hepatitis and HIV 2016

Tackling the issues: Caring for HIV-positive women today | Anna Maria Geretti, MD, PhD, FRCPath

Central and Eastern European Meeting on Viral Hepatitis and HIV 2016

HIV and Pediatrics in Central Europe | Mariana Mărdărescu, MD, PhD

Central and Eastern European Meeting on Viral Hepatitis and HIV 2016

(Abstract) HCV reinfection in HCV/HIV coinfected patients treated for VHC in AIDS Center Prague | V. Aster

Central and Eastern European Meeting on Viral Hepatitis and HIV 2016

(Abstract) Expression of NS4 HCV in liver cells of HIV/HCV co-infected patients | N. Matsiyeuskaya

Central and Eastern European Meeting on Viral Hepatitis and HIV 2016

(Abstract) Chronic Hepatitis C Treatment among HIV/HCV co-infected PWID in Ukraine: communitysupported treatment model experience | T. Barnard

Central and Eastern European Meeting on Viral Hepatitis and HIV 2016